In this work, funded by the National Institute for Cancer Research (NICR, https://www.nuvr.cz/en/), of which the team is a member, the reader will learn that patient organoids (PDOs) excel in high-throughput drug screening due to ease of use, lower cost, and faster results. Patient avatars (PDX), on the other hand, offer a more physiologically relevant model that allows for comprehensive drug evaluation and study of the mechanism of action. The choice between PDO and PDX depends on the focus of the research, resources, and required parameters on the tumor microenvironment. Pancreatic cancer is one of the least researched malignancies with a very poor clinical prognosis.
Link to the article: https://doi.org/10.1016/j.biopha.2024.117750
